Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
NCT02718066
Adenocarcinoma, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial DetailsNCT Number: NCT01106781
This is a descriptive observational study. The primary objective is to explore the EGFR gene mutation status in early stage NSCLC with adenocarcinoma histology after complete resection. The patients should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation in regular medical practice.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Research Site, Beijing, Beijing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to 3 months
Time frame: up to 3 months
Time frame: up to 3 months
AstraZeneca
Industry
A Non-interventional Survey on the Epidermal Growth Factor Receptor (EGFR) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
Acronym: ICAN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02718066
Adenocarcinoma, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial DetailsNCT05348668
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hefei, Anhui, China
View Trial DetailsNCT04702009
Advanced Lung Carcinoma, Bronchial Neoplasms
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT06477055
Bronchial Neoplasms, Carcinoma, Bronchogenic
Changsha, Hunan, China
View Trial Details